A New Frontier in Colon Cancer Care: FDA Approves Atezolizumab for Stage III dMMR Tumors
October 9, 2026 — In a landmark decision that promises to redefine the standard of care for patients with high-risk colorectal malignancies, the U.S. Food and Drug Administration (FDA) has…











